Webinar:

The use of 3D Bioprinting to achieve uniformity and reproducibility of in vitro skin models

Sponsored by: Biogelx Limited

Focused on:

  • Bioprinting
  • Tissue Engineering

Date: 21 January

Days to go: 43

Time: 3PM London/10AM New York

Development of a reproducible and standardised in vitro skin model for pharmaceutical and medical applications.

Commercially available tissue-engineered skin has remained elusive despite extensive research because the multi-stratified anisotropic structure is difficult to replicate in vitro using traditional tissue engineering techniques.

In the last few years, bioprinting has opened brand-new opportunities for the production of these models, providing a more efficient approach in terms of precision and homogeneity and offering experimental versatility. Such relevant skin equivalents can be used in regenerative procedures, as robust models in toxicological and cosmetic tests and as a tool in basic biological research. The development of new materials which are compatible with both bioprinting procedures and established biological structures is essential to the growth of the entire field.

In this webinar, we will discuss the potential of 3D printing of biomaterials and cells and maturing them in a bioreactor to create functional skin in the lab. We will discuss the requirements of materials used in bioprinting and introduce a versatile peptide bioink technology and discuss the application of these materials in real research environments. Furthermore, we will present a case study on a recently developed in vitro skin model which utilises synthetically made but biologically active bioinks.

The novel skin model is generated using Regemat3D™ extrusion-based bioprinter and Biogelx™-INK-GFOGER, which offers the advantage of creating a more accurate and standardised skin model. The uniformity and reproducibility achieved combining these technologies mean this novel in vitro skin model has the potential to act as a skin substitute in toxicity testing and potentially form the basis of a future cell therapy application.

Presented by

José Manuel Baena, Ph.D,

Founder and CEO at Regemat 3D

José Manuel Baena received a Ph.D. in Biomedicine from the University of Granada, Spain, MSc Engineering from Polytechnic University of Valencia, Spain and TU Braunschweig, Germany, and MSc from Oxford Brookes University, UK. As a biotech entrepreneur, Baena founded BRECA Health Care, a pioneer in 3D printed custom-made implants for orthopaedic surgery, and REGEMAT 3D, a leader in the bioprinting industry. He serves as scientific coordinator of the Tissue Engineering and 3D Printing Platform (PITI3D), IDIPAZ, Hospital Universitario de La Paz, Madrid, Spain and is a research associate in the group "Advanced therapies: differentiation, regeneration and cancer" IBIMER, CIBM, University of Granada, Spain. He is passionate about biomedicine and technology.

Chris Allan, Ph.D,

Development Scientist at Biogelx

Chris is a chemist by training, who received his PhD from the University of Edinburgh in 2018. Since joining Biogelx, he has worked on the development of a range of bioinks based on the company’s proprietary peptide technology. Chris is also closely involved in many of the company’s collaborative projects which are ongoing with groups in academia and industry.

Mario Juárez Rodríguez MSc,

Research associate at the Platform for Tissue Engineering and 3D Printing, La Paz University Hospital, Madrid

Mr. Juarez (MSc.) is a biotechnologist specialized in medical biotechnology and human bioengineering. His research has been focused in tissue engineering, synthetic biology and material science. Currently, he is working in skin tissue engineering in order to set up a facility to produce human skin for clinical applications (rare diseases, toxicology, cosmetics, cancer…)

Key Learning Objectives

  • Understanding the benefits of additive manufacturing in tissue engineering.
  • An introduction of the different possibilities of biofabrication (Bioprinting and Bioreactors) to create functional tissues.
  • Understanding the requirements for bioinks and the peptide technology behind the Biogelx™ product range.
  • Understanding how skin bioengineering is changing medicine from different perspectives: biology, engineering, medicine and business. How construct, analyse and validate a skin equivalent.
  • Case study: Development of a versatile skin model for future pharmaceutical and clinical applications

Audience

  • Research Scientist
  • Product Development Manager
  • Development Scientist
  • Post-Doctoral Scientist
  • Post-Doctoral Researcher
  • PhD Student
  • PhD Researcher
  • Associate Scientist
  • Research Associate
  • Cell Culture Technician
  • Lab Technician
  • Lab Manager
  • Heads of Research and Development
  • CEO
  • CSO
  • Senior Research Scientist
  • Product Development Scientist
  • Pre-Clinical Development Scientist
  • Drug Development Scientist
  • Drug Screening Scientists
  • Tissue engineer
  • CTO
  • Biomedical Engineer
  • 3D Printing Scientist